The BMAL2 Knockout HeLa Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population targeting the BMAL2 gene in HeLa cells. BMAL2 (ARNTL2/MOP9) is a core circadian transcription factor. This polyclonal product comprises a heterogeneous pool of cells with disrupted BMAL2 alleles, facilitating loss-of-function studies without clonal selection bias. The knockout is generated via CRISPR/Cas9-mediated gene disruption, resulting in abrogated protein expression.
HeLa is an immortalized human cervical epithelial adenocarcinoma line widely employed in cancer research. These cells contain integrated HPV18 DNA, whose E6 and E7 oncoproteins inactivate the tumor suppressors p53 and Rb, respectively, conferring high proliferative capacity and experimental tractability. The well-characterized genomic background of HeLa cells provides a reproducible platform for investigating gene function and drug responses.
BMAL2 heterodimerizes with CLOCK or NPAS2 to bind E-box elements, recruiting coactivators such as CBP/p300 to activate transcription of clock genes including PER1, PER2, CRY1, CRY2, and DBP. The expressed PER and CRY proteins subsequently inhibit the BMAL2-CLOCK complex, forming a negative feedback loop that drives circadian oscillations. BMAL2 activity is regulated by upstream factors like REV-ERB??, ROR??, CKI??, and GSK3??, and it participates in HIF-1 signaling, metabolic control, and cell cycle regulation.
In HeLa cells, BMAL2 knockout disrupts circadian transcriptional networks in a transformed background with defective p53 and Rb pathways. This model enables investigation of how circadian clock disruption influences cancer cell proliferation, genomic stability, and therapeutic responses. The polyclonal nature of the knockout population reduces the risk of clonal artifact interference, ensuring that phenotypes are representative of the overall gene-disruption effect.
Researchers can use these cells for circadian rhythm analysis via luciferase reporter assays and RNA-seq, and for mapping clock protein-DNA interactions by ChIP-qPCR. Cancer biology applications include proliferation and drug sensitivity testing, cell cycle analysis by flow cytometry, and metabolic profiling. These cells also serve as negative controls for BMAL2 antibody validation in Western blotting. For additional information or customization, please contact Ascent Research.
